Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial

PURPOSE: This single-center, open-label, single-arm, phase II clinical trial aimed to examine the efficacy and safety of the first-generation EGFR-TKIs combined with chemotherapy among treatment-naïve advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jinghui, Li, Meifang, Chen, Shijie, Weng, Lihong, He, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216733/
https://www.ncbi.nlm.nih.gov/pubmed/34168480
http://dx.doi.org/10.2147/JIR.S313056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216733/
https://www.ncbi.nlm.nih.gov/pubmed/34168480
http://dx.doi.org/10.2147/JIR.S313056

Ejemplares similares